Zynerba Pharmaceuticals, Inc.

NASDAQ:ZYNE

1.3 (USD) • At close October 10, 2023
Bedrijfsnaam Zynerba Pharmaceuticals, Inc.
Symbool ZYNE
Munteenheid USD
Prijs 1.3
Beurswaarde 70,121,220
Dividendpercentage 0%
52-weken bereik 0.25 - 1.4
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Armando Anido MBA
Website https://www.zynerba.com

An error occurred while fetching data.

Over Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and

Vergelijkbare Aandelen

Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc.

ATXS

11.54 USD

Acasti Pharma Inc. logo

Acasti Pharma Inc.

ACST

3.37 USD

Ocuphire Pharma, Inc. logo

Ocuphire Pharma, Inc.

OCUP

1.17 USD

NexImmune, Inc. logo

NexImmune, Inc.

NEXI

0.218 USD

Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc.

AQST

5.15 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)